ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1330

High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients

Marianne van den Broek1, L. Heimans2, S. le Cessie3, B. Siegerink3, H.K Ronday4, K.H. Han5, P.J.S.M. Kerstens6, T.W.J. Huizinga2, W.F. Lems7 and C.F. Allaart2, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Medical statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Haga Hospital, The Hague, Netherlands, 5Rheumatology, MCRZ hospital, Rotterdam, Netherlands, 6Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 7Rheumatology, VU University medical center, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, body mass, combination therapies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

High BMI is associated with decreased response to initial combination therapy in recent onset RA patients

 

Background/Purpose: A diminished response to combination treatment with a fixed dose of TNF-blocker infliximab (IFX) has been reported in patients with established RA and a high BMI.  The association between BMI and response to therapy might also exist for other treatment regimens through inflammation and/or pain.

The association between high body mass index (BMI) and treatment response was assessed in a treat to target cohort with recent onset RA patients.

Methods: All patients from the BeSt study (n=508), in which patients were randomized to initial monotherapy or combination therapy with prednisone or infliximab (IFX) were included in the analyses. Response (DAS≤2.4) to disease activity steered treatment (first dose and after 1 year) was compared between patients with a BMI <25 and ≥25, using Poisson regression analyses. Several components of disease activity and functional ability during the first year were compared using linear mixed models. Joint damage progression in year 1 and over 8 years of treatment was compared using radiographs scored with the Sharp/van der Heijde Score.

Results: High BMI was independently associated with decreased treatment response to initial therapy, RR: 1.20 (95% C.I. 1.05-1.37). After stratification for initial treatment group, the effect was found for combination therapy with prednisone: RR 1.55 (1.06-2.28) and for combination therapy with IFX, RR 1.42 (0.98-2.06). The RRs for failure after one year in these groups were 1.46 (0.75-2.83) and 2.20 (0.99-4.92) respectively. A similar association was found for response to delayed combination therapy with IFX, after adjustment for selection bias related to previous failure on DMARDs. In the first year of treatment, patients with a high BMI had higher disease activity and worse functional ability, with more tender joints and a higher VAS global health, but not more swollen joints and similar systemic inflammation. Patients with high BMI did not have more damage progression over time.(figure 1)

Conclusion: High BMI was independently associated with decreased response to initial combination therapy with prednisone and to initial and delayed treatment with infliximab, During DAS≤2.4 targeted treatment, patients with a high BMI experienced more pain, but not more swelling or systemic inflammation. Joint damage progression over 8 years was similar for patients with high and normal BMI.

Figure 1: functional ability and joint damage progression in year 1 for patients with normal and high BMI


Disclosure:

M. van den Broek,
None;

L. Heimans,
None;

S. le Cessie,
None;

B. Siegerink,
None;

H. K. Ronday,
None;

K. H. Han,
None;

P. J. S. M. Kerstens,
None;

T. W. J. Huizinga,
None;

W. F. Lems,
None;

C. F. Allaart,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-body-mass-index-is-associated-with-decreased-response-to-initial-combination-therapy-in-recent-onset-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology